Sarcoma News

In August, the FDA issued several approvals and review designations across the field of oncology. HemOnc Today has compiled a list of the past month’s approvals, updates and submissions.

The FDA granted the PapGene liquid biopsy test breakthrough device designation for the detection of cancer among people aged older than 65 years, according to the manufacturer.

Adolescents with cancer treated at pediatric institutions had greater health care use and higher costs than those treated at adult institutions, according to a Canadian population cohort study.

Sixty-five percent of adult survivors of childhood cancer experienced financial hardships related to their earlier diagnosis, according to findings from a cross-sectional study.

Individuals who received monthly high concentrations of vitamin D without calcium did not appear to have lower risk for cancer, according to findings from a post-hoc analysis of the Vitamin D Assessment study.

The FDA granted orphan drug designation to CLR 131 for treatment of Ewing sarcoma, according to the agent’s manufacturer.

Researchers from the American Cancer Society identified trends in disparities and outcomes for cancer over the last few decades in an effort to highlight the need for better quality care for all individuals with cancer, according to a report published in CA: A Cancer Journal for Clinicians.

Rivaroxaban significantly reduced venous thromboembolism recurrence among patients who had cancer and VTE compared with dalteparin, according to findings published in Journal of Clinical Oncology.

Thirty-one percent of adult survivors of childhood cancer reported a lack of concern for future health and 40% reported a lack of concern regarding risk for future cancer, according to study findings.

CHICAGO — Sophia Randolph, MD, PhD, chief medical officer at Alexo Therapeutics, spoke with HemOnc Today at ASCO Annual Meeting about ALX148.